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ABSTRACT
Making the case to improve the availability and reliability of public health
spending data: An examination of preventive care expenditures among highincome countries from 2000 to 2019
By
Kristy T. Hayes
September 13, 2021

Background: Averting the onset of disease or detecting disease early through preventive care
can improve overall population health. It is well recognized in the literature that preventive care
has been historically undervalued and underinvested, despite a growing body of evidence on the
impact of total health funding on economic growth and health outcomes. The relationship
between health outcomes and public funds spent on prevention has not been thoroughly
investigated. The purpose of this dissertation is to examine the relationship between
government funds spent on preventive care and health outcomes. To do this, an examination of
preventive care expenditures was conducted using data from countries in the Organization of
Economic Cooperation and Development (OECD).

Methods: A three-phased methodological approach was used to gather evidence on preventive
care expenditures. The first phase was a descriptive analysis of preventive care
spending. The second phase investigated four paired relationships between preventive care
expenditures and health outcomes among OECD countries. A cross-correlation function was
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used to examine the temporal association of these relationships from 2000 to 2019. Lastly,
economic and demographic factors were applied to delineate between country differences.

Results: On average, OECD countries spent approximately 3% of total health funds on preventive
care. Ten countries had positive cross-correlations, five countries had negative crosscorrelations, and the remaining 15 had inconclusive results. This dissertation could not
determine a relationship between health outcomes and public funds spent on preventive care.

Conclusion: These results indicate the importance of high-quality data and consistent reporting
to build evidence on government expenditures on public health on health outcomes. Without
credible and reliable health spending data, it is challenging to study the possible relationship
between preventive care spending and health outcomes. Establishing a global minimum
standard of public health programs can serve as a key input to developing benchmarks to meet a
basic public health standard. This may offer a pathway for more consistent, reliable and regular
reporting of expenditure data. Lastly, there is a need for available, accessible, and actionable
expenditure data from economically and geographically diverse countries to strengthen fiscal
capacity.
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Introduction

Background

Governments have a responsibility to promote health and prevent disease. The need arises as a
result of market failures, ubiquity of unhealthy products, or inequitable public policies that
adversely affect health, among other reasons.1 Governments are responsible to protect the
population’s health based on three accepted norms.2 Government’s first responsibility is to
disseminate free and transparent information to promote healthier lifestyles, such as front-ofpack labeling on food items or cigarette packages.2 The second is to protect people from harm
caused by others, such as impaired driving or second-hand smoking, which can lead to changes
in social norms.2 The third responsibility is to use their authority to protect entire populations
regardless of socioeconomic status, like regulating air quality or eliminating artificial trans-fats
from food.2 These obligations aim to prevent diseases and disabilities as a result of health factors
or social determinants of health.3 Fulfilling these obligations depends on political will and
funding, but both factors can fluctuate with election cycles and the political climate because,
despite the population level gains, the individual-level benefits are perceived to be too small.4

Governments can measure, report, and monitor health spending to become better stewards of
public funds and ensure sustainability of the health system.5 Fiscal stewardship of public funds is
the ability to maintain the viability of the financial condition of effective and efficient public
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health functions, institutions and systems, and articulate their financial conditions in terms that
are familiar to decision makers and the public.5,6 Ensuring sustainability is the ability to maintain
and manage service coverage from local to national levels. This is critical during a surge for
resources during natural and humanitarian emergencies.5,6 To achieve fiscal stewardship and
sustainability, a uniform chart of accounts and standard financial management practices and
systems are essential to validate the magnitude and impact of public health actions. This allows
health leaders to be sound fiscal stewards and ensure a strong public health system.

An internationally accepted standardized framework called the System of Health Accounts (SHA)
was developed by the Organization of Economic Co-operation and Development (OECD) in 2000
to support countries in accounting for expenditures in health.7 Founded in 1961, the OECD
consists of 38 mostly high-income countries, representing 80% of the world’s trade and
investment.8 The OECD collaborates with other member countries to set standards and support
policy development to strengthen economies and to establish more equitable societies.9 The
SHA is one of the tools established by the OECD to account for health expenditures in support of
its mission and goals. It is considered the gold standard for monitoring health spending because
it provides a governance framework to report health expenditures from diverse and complex
health systems.10 Data on health expenditures are easily accessible and regularly updated from
OECD countries. These countries are economically and demographically similar and have
advanced fiscal capacity.11 Expenditure data from low- and middle-income countries are hosted
online but are in formats that do not allow for easy retrieval and are not regularly reported or
updated.
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Before the emergence of SARS-CoV-2, the causative agent of COVID-19, the average annual total
health expenditure across OECD countries was approximately 8% of GDP and 2.8% of annual
health expenditures were spent on prevention.1,12 Though not a formal recommendation, the
literature suggests that countries should spend 5% of their GDP on health.13,14 However, none of
the normative setting agencies, like the World Health Organization (WHO), have formally
adopted this approach.13 A recognized optimal or minimum level of funding for preventive care
is not currently available or recommended in the literature.

Purpose
While it is well recognized in the literature that public health has been historically undervalued
and underinvested, the relationship between government spending on preventive care and
health outcomes has not been thoroughly investigated.15–17 The government has the
responsibility to prevent disabilities and diseases through programs, policies, and strategies for
the sake of public health protection.2 Therefore, the purpose of this dissertation is to build
evidence on the relationship between government spending on public health and health
outcomes. This dissertation does not account for private expenditures or individual out-ofpocket expenses for preventive care services. This study uses health expenditures reported by
OECD countries following the SHA framework, which has its limitations in portraying spending in
public health. The SHA uses the traditional definition of prevention of averting injuries, diseases,
and their complications. This definition excludes the evolution of public health in its 3.0 era
which is inclusive of cross-sectoral collaboration to address social determinants of health.18
While SHA circumvents the challenges to account for funds that address social determinants of
12

health, the SHA definition of preventive care expenditures also limits the depth of public health
practice.1 Because expenditure data that characterizes the breadth of public health and
represents an array of countries is not currently available, this study attempts to make
inferences on public health spending using existing data to examine the extent of government
expenditures on prevention and its relationship with health outcomes. As a result, preventive
care, government, and public health spending or expenditures are used synonymously
throughout this paper. This study uses descriptive analyses to examine results from a crosscorrelation function. This function investigated the temporal association between preventive
care expenditures and health outcomes among OECD countries from 2000 to 2019.

Undertaking this analysis provided a process to consider the reasons for the limited empirical
analysis on public health expenditures. This could be the result of the complex multisectoral
nature of health promotion and disease prevention activities. The prevailing definition of
prevention addresses social determinants of health, which are social and economic factors that
influence health.3,18–20 Programs that address social determinants of health inherently partner
across sectors.3 Extracting funding levels or determining sources of funds can be overly
complicated and difficult to collect if multiple stakeholders are involved. Another possibility for
the lack of robust evidence on public health expenditures is the time lag from prevention to
population impact.21 Because the benefits of preventive measures accrue over a long period of
time, it is challenging to attribute any improvements in population health or health outcomes to
them. Having available and reliable expenditure data provides the basis to translate the
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magnitude and impact of public health actions which can be used to justify sustainable and
predictable funding.

Significance

Prevention measures are critical because it is inevitable for a portion of the population to
develop a disease, whether a result of genetics (a direct pathway) or social determinants of
health (an indirect pathway).15 The public has the responsibility for their own health, but the role
of government is to implement public health action to make the healthy choice the default
option.2

It is especially difficult for governments to earmark funds for prevention during an economic
crisis. For example, during the Great Recession, 2007 to 2009, high-income countries put into
place austerity measures making significant cuts to public health budgets and condensed or
closed public health offices.11 Figure 1 compares preventive care spending as a percent of total
health expenditures among European countries in 2008 and 2015. In eight of the 11 countries,
there was a decline in the share of funding dedicated to prevention. This was a result of a
tradeoff in funding public health and other industries to boost economic growth.11 Similarly, U.S.
prevention spending struggled to recover from budget cuts during the Great Recession in which
it was reduced from 3.2% in 2002 to 2.7% of total health spending in 2014.22
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Figure 1. Preventive care as a percent of current health expenditures, 2008 and 201511

The emergence of COVID-19 revealed fault lines within public health. Persistent
underinvestment in public health structures, capacity, and resources as well as mismanagement
brought on significant challenges to control the pandemic. It impeded the implementation of
primary and secondary prevention measures to properly and rapidly screen and surveil the
population for the virus.23 The lack of a strong public health infrastructure may have contributed
to the misinformation regarding prevention measures, like the use of face masks, social
distancing, and COVID-19 vaccine hesitancy.24,25 The aftermath of the COVID-19 pandemic can
usher in a sea change for public health. It can be the catalyst to significantly fortify public health
in its mission to prevent and control chronic conditions, mitigate the susceptibility to infectious
diseases, and improve capacity for emergency response.26 But for a meaningful upgrade of its
capacity and infrastructure, public health needs to be impervious to budget cuts. Providing the
economic and epidemiological justification can influence policy makers to secure sustainable and
predictable financing for public health.
15

Economic evidence may offer a rationale to safeguard public health from being snubbed from
prolonged sustainable public funding. The COVID-19 pandemic exposed how public health and
the economy are intertwined. The economic disruption from the pandemic has had a global
impact. Some models estimate the total impact of lockdown restrictions at approximately 9% of
the global GDP. The economic loss in the U.S. is approximately $16 trillion or more than twice as
much as the money spent on all wars, including in Afghanistan, Iraq, and Syria, the U.S. has
fought since September 11, 2001.27 The global cost of premature deaths from COVID-19 is
approximately $5.9 trillion, with high-income countries bearing most of the burden of at least
$3,700 per person.28

Investing in preventive care can make an impact beyond geopolitical borders. The pandemic
provides an opportunity for high-income countries to recognize their own ineffectiveness in
preventing, detecting, and responding to highly communicable diseases, like COVID-19. In OECD
countries, infectious diseases account for a small share of the overall disease burden, but they
can reconcile their failure to adequately control the virus because of underinvestment in public
health. In doing this, they can achieve their goals of stimulating economic progress and
recommending equitable social policies in low- and middle-income countries.8 OECD countries
have the platform to encourage the adoption of public health prevention policies, practices, and
systems to combat emerging infectious diseases, interrupt the growth of chronic conditions, and
prepare for the next pandemic.
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The COVID-19 pandemic laid bare the fragility of public health systems globally. With chronic
underfunding, politicization of public health, and resulting economic ramifications, it is clear
there is a need for further analysis of prevention expenditures and outcomes. Linking monetary
data with non-monetary data provides an opportunity to generate information on preventive
care spending and the implications for allocating scarce resources. This dissertation aims to build
evidence on the relationship between preventive care spending and health outcomes. This
analysis attempts to provide the basis in supporting the case for available and reliable public
health spending data.
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Literature Review

Background

Population health and health spending have an iterative relationship with human capital,
individual income, and workforce productivity.29 The seminal theory on the demand for health,
developed by Michael Grossman in 1971, modeled health as a commodity which naturally
depreciates over time with age.30 The model posits investments in health increase the health
stock of individuals. Investing in someone in poor health yields a greater marginal benefit relative
to healthy individuals because they have more health to gain. Grossman assumes that more
education shifts marginal benefits upwards so that the better educated have more time being
productive and less time in poor health. From this theory, improvements in health strengthens
workforce productivity and positively influences economic growth, thus sustaining spending on
health increases health stock.30

The theory is supported by research by Bloom and colleagues (2019) that studied the effects of
health on economic growth based on wages.31 Their results indicate that a 10% increase in adult
survival rates is associated with a 9% increase in labor productivity with health status influencing
differences in wages between countries. Bloom (2004) also estimates a one-year improvement
in a population’s life expectancy increases GDP by 4%.29,32 Their findings suggest public health
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prevention measures contribute to economic development. This incentive of improving overall
economic growth should motivate governments to want to invest in public health.29

There is a constant struggle to advocate for public funds within health, like between preventive
and curative care, or between health and social programs, such as education or social
protection. This competition is a zero-sum game since preventing a disease contends for the
same limited resources that address social determinants of health or treatments for illnesses.17
Securing ongoing and predictable government support for preventive care is often mired in
politics and can be exacerbated by election cycles. Appealing to public officials to invest in public
health is difficult because the cumulative benefits from public health interventions occur over
time and across administrations.21 It is also challenging to count and report the number of deaths
or disabilities averted as a result of a public health intervention.21 This makes it difficult to
attribute its benefit to the intervention. For example, fluoridation in drinking water contributes
to the reduction of tooth decay.21 But it is difficult to credit water fluoridation to good dental
health or to count the number of people who benefit from it as a result of other factors
supporting good dental health. 21 Consequently, public health budgets and political will stagnate,
leading to chronic underinvestment in the health system for preventive care.

High overall government spending in health does not always correlate to better health
outcomes. It is well documented that the U.S. spends more on health than any other country but
continues to produce poor health outcomes.33,34 The Commonwealth Fund’s comparison of
health expenditures in countries in the Organization of Economic Cooperation and Development
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(OECD) found that the U.S. spends more than twice as much on health than any other OECD
country but has worse health outcomes.35 The most recent survey suggests that the U.S. has the
lowest life expectancy, highest burden of chronic disease, its obesity rate is twice that of the
OECD average, and the U.S. has the highest number of preventable hospitalizations.35 Figure 2
presents health expenditures as a percent of GDP among OECD countries. A cross-sectional
analysis using 2016 data found that the 10 next highest income countries spent a range of 9%
(Australia) to 12% (Switzerland) of their GDP on health. The U.S. is an outlier, spending nearly
17% of its GDP in 2018 on health, due to high administrative costs and pharmaceutical
spending.33
Figure 2. Health Spending as a percent of GDP among OECD Countries35

Note: GDP is adjusted for differences in cost of living, legend shows 2018 data

Health expenditure as a share of GDP and per capita are two measures that summarize the
overall availability of funding for health. However, health expenditure as a portion of GDP may
20

have a distorted appearance due to external factors. In a perspective piece, Brian Turner (2018)
explains this distortion from two angles based on an experience in Ireland in 2008 and 2015.36 In
2008, in the midst of the Great Recession, it appeared that Ireland spent more on health as a
proportion of GDP compared to other OECD countries. But the measure was misleading, as it
was a result of a contracted economy and not because Ireland increased their health spending.36
In 2015, because their GDP increased by 26%, health spending as a proportion of GDP declined,
despite a 9% increase in health spending. Health spending as a share of GDP may not provide an
accurate picture on the state of health expenditures in a country and could have implications on
health equity.37 A per capita measure of health spending is a better indicator of health
expenditures, translated in purchasing power parity (PPP), because it regards population size and
mitigates externalities that could distort between country comparisons.36 The average per capita
health expenditure among OECD countries was US$3,994 in 2018.38 The U.S. remains an outlier
with a health spending per capita of over US$10,000 that same year. Other high-income
countries like Canada, Germany, France, and Japan spend 50% less than the U.S. per capita
health spending.38

Given the tightening of public funds as a result of the Great Recession, studies emerged to assess
health spending and return on investment in health. Despite growth in health spending in 2015
and 2016 of approximately 3.3%, there was a significant reduction in overall per capita spending
in OECD countries by an average of 2.0% in 2017.38 This is particularly relevant in countries
hardest hit by the Great Recession. Austerity measures, which resulted in sustained annual
reductions in overall health spending in subsequent years resulted in unintended negative
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effects on the public health system in many European countries.39 Declines in health spending in
high-income countries have been associated with stunting economic growth.39–41 In 2017,
Masters and colleagues (2017) review of return on investments of public health interventions in
high-income countries found that any reductions to public health budgets at the national level in
the form of savings represents a “false economy”.4 This is because any short-term economic
advancements will falter driven by future costs of a weakened health sector and lost economic
productivity.4

Publications on cross-country comparisons of health spending are typically based in OECD
countries. This is because expenditure data are publicly available, easily accessible, and updated
regularly. OECD countries follow the System of Health Accounts (SHA), a standard framework to
report health expenditures. The SHA links the pathway of health expenditures by the financers
(who pays), health providers (who uses the funds), and the purpose for the funds (what is
consumed).7 It accounts for consumption of health as curative care, rehabilitative care, longterm care, ancillary services, medical goods, preventive care, governance and health system
administration, and other health services. The proceeding section provides an overview of the
literature on total health spending and its relationship on various measures of health outcomes.
This is followed by a review of the available literature on preventive care spending.
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Health Spending

Cross-country comparisons of health expenditures assess the efficiency in spending public funds.
It examines whether countries spend less and achieve the same health outcomes or spend the
same level and achieve better health outcomes.42 Researchers use a number of indicators as a
proxy for health, such as death statistics like mortality rate, infant mortality, or years of life lost
(YLLs).42 It can also be expressed as longevity indicators like life expectancy (LE), years lived with
disability (YLDs), disability-adjusted life years (DALY), or healthy adjusted life expectancy
(HALE).42

A limited number of studies use HALE as a proxy for health outcomes. HALE is a summary
measure of the average number of healthy years lived at different ages in a given country.43 It is
calculated using life tables and accounts for disease prevalence that lead to death and disability.
The Global Burden of Disease use HALE as their outcome measure to account for the severity of
a wide range of health states.44 It is also a key indicator for WHO’s impact measurement to
monitor inequality and improve equity.45 Poullier and colleagues (2003) studied the relationship
between health spending and HALE in 191 countries.46 They found that the range of health
spending and HALE vary among countries which suggests that the level of funding and the
efficiency in which funds are spent could affect health outcomes.46 These results A Canadian
analysis of health expenditures from 1980 to 2012 found that health spending per capita
increased between 1.0% to 2.2% per year, but HALE, on average, increased 0.3% during that
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time period.47 This indicates that the yearly incremental increase in spending produces little
improvements in health outcomes.47

LE is a common measure of health outcomes to assess health systems and resources. Results
from studies examining this relationship are mixed and, at times, contradictory on the role
health spending plays in improving LE. Jaba and colleagues (2014) found a significant positive
relationship between health expenditures and LE in high-income countries.42 They suggest that
differences in health financing systems, like a national health system compared to multiple
insurance schemes, explain discrepancies in health outcomes between countries. Deshpande et
al. (2015) also found a significant positive correlation between health expenditures and LE in
developed countries, but this correlation was not found among developing countries.48 They
postulate that health spending in developed countries may be more efficient, whereas the
quality of healthcare could matter more than funding levels in developing countries. Obrizan and
Wehby (2018) analyzed health expenditure per capita in 175 countries and found that countries
with lower LE have the greatest need for increased health spending.49 Improvements in mortality
have the potential to strengthen economic growth by inherent gains in human capital and
therefore increased health spending in countries with low LE will see greater returns in
longevity.49 Similarly, Cutler and collaborators (2006) assessed the value of increased spending in
health on gains in LE from 1960 to 2000 in the U.S.50 They found that LE rose and the amount
spent on health from birth increased from $14,000 to $83,000 in 1960 to 2000, respectively.50 It
suggests that the benefits received by the population are worth the increase in spending with LE
increasing 6.97 years during the study period.50
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Other studies allude to a more ambiguous relationship between health spending and LE. Nixon
and Ulmann (2006) analyzed the relationship between health expenditures per capita as it
relates to LE at birth and infant mortlity.51 Their results indicate that health spending contributes
to the reduction of infant mortality but marginally contributes to LE. Aísa and colleagues (2014)
studied the influence of public and private health expenditures as a share of GDP on LE.52 Their
results were inconclusive because public health spending was significant at the 10% level of
significance only when fixed effects were considered. They recommend taking into account the
type of health system when assessing spending on health outcomes. Ven den Heuvel and Olaroiu
(2017) studied the relationship between LE and spending as a share of GDP in health, education,
and social protection controlling for the quality of healthcare system among 31 European
countries.53 Their results indicate that while all three types of expenditures have a statistically
significant positive correlation, social protection spending contributes to longer LE more than
health spending. Baltagi et al. (2012) found that health spending has a significant, but mild,
effect on LE among OECD countries.54 They suggest that the rise of health spending is driven by
advances in medical technologies. Van Baal et al. (2013) denotes the difficulties in demonstrating
the link between LE and health spending as a result of health system complexities and the
inability to quantify the effects of technologies in advancing LE.55 Indeed, advances in medical
technology can contribute to increases in LE.50,56 Technological innovations in curative care lead
to long LE and an aging population as a result of reductions in mortality from cardiovascular
disease and deaths in infancy.50,56 Aging and long LE are seen as drivers for increases in health
spending in developed countries, driven mostly by long-term care services.53
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Most research on health spending focuses on total health expenditures and, of those, crosscountry analyses are typically on high-income countries or exclusively on the U.S. Very little
empirical research has been done to examine preventive care expenditures. The following
presents economic and epidemiologic analysis of public health prevention and an exploration
that may explain the deficiency of robust analysis.

Preventive Care Spending

A 2015 analysis found that OECD countries spend less than 3% of total health expenditures on
preventive care and 60% on inpatient and outpatient curative care services.1,38 Figure 3
illustrates the allocation of funds across preventive care among OECD countries in 2015. The
variation is likely due to different measurement and accounting practices. More preventive care
funds are spent on these individual-level services (60%) than population-based services (40%),
though it is well established that population-level interventions have a greater impact than
individualized efforts.1,35 Of the funds spent in clinical preventive services, a large portion were
allocated to activities that lack cost-effective evidence.1 OECD countries spent over 40% of
expenditures on healthy condition monitoring programs, which include wellness checkup visits
and dental exams. These interventions have little evidence on their cost-effectiveness.1 The
absence of high-quality evidence implies that less should be spent on these programs or
alternatively high costs could contribute to the large proportion spent on these programs.
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Conversely, in 2015 countries spent less than 10% on immunization and screening programs,
which are considerably more cost-effective.1
Figure 3. Prevention expenditure by service type among OECD countries, 20151

With preventive care, there are epidemiologic and economic ramifications. The allocation of
limited resources in health is essentially a policy issue that needs to weigh both sides. Due to
limited public resources, there is an inherent tradeoff in the available funds allocated between
preventive and curative care.17,57 Because prevention is not always 100% effective in part due to
social determinants of health or genetics, a portion of the population will ultimately develop
preventable diseases.15 Therefore, funds have to be allocated between curative care to treat an
illness and preventive care to avert the disease.17 Using the OECD expenditure data, Wang
(2018) suggests a nonlinear relationship exists between preventive and curative care
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expenditures as it relates to economic growth.58 The relationship derives from the law of
diminishing returns. Though prevention can improve health outcomes and workforce
productivity—which, in turn, stimulates economic growth—too many resources dedicated to
prevention may crowd out the available funds for curative care.17 There is a point where too
much funding for preventive care can reduce health outcomes overall because of its detrimental
effect on spending for therapeutic innovations.17 Consequently, Wang (2018) recommends an
optimal level for prevention and curative care of 0.44% and 10.96% of GDP, respectively, to
sustain economic growth.17 This recommendation is not widely implemented. For example in a
study by Ethgen and colleagues (2018), which estimated that the proportion spent on prevention
was between 0.07% and 0.41% of GDP among seven OECD countries.59 They acknowledged the
limitations associated with OECD expenditure data relating to incompleteness and reliability of
the cost components, and lack of consistent reporting. Additionally, Wang’s recommendation is
for sustaining economic growth, but no empirical research to date exists on the optimal or
minimum level of preventive care to improve population health.

From an epidemiological standpoint, there is evidence for spending resources on public health.
Between 1985 and 2012, seventeen articles were published studying the relationship between
total public health spending and various health outcome measures in the U.S.60 The evidence
suggests that increases in spending lead to improvements in population health outcomes. For
example, in an analysis of U.S. public health departments between 1993 and 2005, Mays and
Smith (2011) found a positive relationship between public health spending and preventable
deaths.16 They saw that an increase of 10% in spending was associated with a 6.9% decrease in
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infant mortality and 3.2% reduction in cardiovascular disease-related deaths.16 Similarly, Ransom
and colleagues (2012) found a positive association in improving childhood immunization
coverage rates when state and federal levels align financing to local needs.61

Several studies and commentaries underscore the paradox of the value of preventive care and
its expectation to deliver cost saving.57,62,63 Louise B. Russell reviewed the cost-effectiveness of a
wide range of prevention activities and estimated 80% of preventive services add to medical
spending instead of achieving any cost-savings.57 Frequency of care is one reason why preventive
care adds to medical spending. For example, cervical cancer screening on an annual basis
increases medical costs, but healthy women screened every 3-5 years is cost-effective compared
to no screening.57 By following approved guidelines for preventive clinical services does may not
add to medical spending but also does not achieve cost savings. Targeting individuals at-risk who
are more likely to benefit from prevention is another determinant of cost-effectiveness.57 For
example, increasing the frequency of screening young men who have sex with men for HIV to
every 3 months compared to existing patterns of HIV screening has been shown to have an
incremental cost effectiveness ratio of $4,500 per quality-adjusted life years (QALY), which is
considered highly cost-effective, and gain 4.28 quality adjusted years.64 Prioritizing cost-effective
prevention activities and following evidence-based recommendations and guidelines from
groups like the U.S. Preventive Service Task Force offer the ability to invest in prevention to
reach those most likely to benefit.

29

From an economic perspective, the cost-effectiveness, and the less likely case of cost-saving,
preventive care interventions depends on the intervention’s effectiveness and implementation
strategies, including targeting the population most likely to benefit.57From an epidemiologic
perspective, preventive care overall is effective in improving population health. Some clinical
preventive services, like childhood immunizations, smoking cessation, and counseling on daily
aspirin-use among high-risk patients with cardiovascular conditions, have proven to do both –
improve health and report a net savings.65 Several articles state that prevention efforts are both
undervalued and underinvested.15,16,21,66,67 For example, tobacco cessation programs have
proven to be effective interventions and reduce long-term costs. However, between 2008 to
2011, spending on tobacco cessation programs among states in the U.S. represented 13% of the
CDC’s recommended funding levels.68 Funding for state and local health departments in the U.S.
have declined by 17% over a decade.69 However, amid the COVID-19 pandemic, the allocation of
over $300 billion supplemented public health agencies to prevent infections and control its
spread.70 But the challenge of effectively and efficiently spending funds surfaces for agencies
that have faced prolonged underfunding.70 Consequently, there has been calls for mandatory
funding from the government replacing annual discretionary appropriations in which public
health agencies are vulnerable to budget cuts.71 Whether public health receives mandatory
funds or supplemental funding, a robust tracking system is needed to help build efficiencies in
spending, develop good governance, and become strong fiscal stewards of public funds. 69,72
Without credible and reliable spending data undermines the development of evidence
supporting prevention spending and the interplay between their value and investment.16
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Conclusion

The societal benefits of public health prevention efforts echo throughout high-income countries.
Successes in immunizations and water, sanitation and hygiene infrastructure have drastically
reduced the burden of infectious diseases in high-income countries. Evidence for this success is
most notable in the reduction of infant mortality falling from 3.3 to 0.6 deaths per 1,000 live
births from 1960 to 1995 in the European Union.51 However, more can be done within health
systems and through public policies to promote healthier behaviors, reduce noncommunicable
diseases, and safeguard for the next pandemic.

The current annual average of approximately 3% of total health spending on preventive care
among OECD countries is relatively small considering its cost-effectiveness and societal benefits.1
Chronic underinvestment and underutilization of preventive care indicates that governments
may have normalized a reactionary response to health preferring to treat instead of preventing
disease or disability. Governments have a tendency to invest in treatment over prevention due
to the immediacy of results in curative approaches.73 However, the current level of spending in
preventive care may be untenable to manage the burden of chronic diseases that high-income
countries are facing and the recurrent threats of emerging infectious diseases.

While there is a growing body of evidence on the relationship between overall health
expenditures and health outcomes, albeit the direction of the relationship is ambiguous, the
literature on preventive care spending and its relationship with health outcomes remains elusive.
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This might be a result of the challenges to account for preventive care spending across multiple
sectors, the failure to achieve cost-savings, or lack of evidence on the time lag for prevention to
affect the population. The link between population health and preventive care spending requires
more in-depth research to inform policy makers on the health status of the population and
performance of health systems. This dissertation attempts to bridge that gap and offer evidence
that addresses funding and its contribution to preventative care. In doing so, this study makes
the case for the need for reliable and available spending data to make a robust investigation of
preventive care expenditures.
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Methodology

Introduction

The approach for the study is exploratory to build evidence for future work that can bring in
more complex statistical techniques if more higher quality data is available. The following
describes a three-phase methodological approach. The first phase is a descriptive analysis of
preventive care spending to illustrate the share of healthcare-related spending dedicated to
prevention. Second, this study hypothesizes a positive association between past government
preventive care expenditures and health outcomes at the national level. This was tested using a
discrete time series cross-correlation function which retrospectively examined the time lag
during a 20-year period. The cross-correlation examined four paired relationships between
preventive care spending and health outcomes Third, the differences between countries were
examined using economic and demographic factors.

Country Selection

The Organization of Economic Co-operation and Development (OECD) consists of 38 high- or
upper-middle income countries across the globe and was established to strengthen crosscountry collaboration and promote sustainable economic growth policies.12 OECD member
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countries are presented in Figure 4.9 OECD countries were selected for this analysis because
expenditure data is publicly available, easily accessible, and regularly updated. Preventive care
expenditure data from low- and middle-income countries during this study’s period of analysis
were unavailable or not easily retrievable. Accordingly, this study examined preventive care
expenditures from OECD countries.
Figure 4. OECD member countries

OECD member countries:
Australia, Austria, Belgium, Canada, Chile, Colombia, Costa Rica, Czechia, Denmark, Estonia, Finland, France, Germany, Greece,
Hungary, Iceland, Ireland, Italy, Israel, Japan, Korea, Latvia, Lithuania, Luxembourg, Mexico, Netherlands, New Zealand, Norway,
Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, the United Kingdom, and the United States.
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Analysis

Given the nascent area of research in preventive care spending, this dissertation presents
additional evidence to meaningfully study funds dedicated to health promotion and disease
prevention. In 2017, the OECD released a report summarizing preventive care expenditures
among OECD countries from 2005 to 2015.1 The first phase of this analysis draws its motivation
from this previously released report. A selection of their analysis was reproduced and extended
to this study’s period of analysis from 2000 to 2019.

The descriptive analysis includes the change in preventive care expenditure per capita compared
to the annual economic growth rate and total health spending from 2000 to 2019. Using the
most recent available year of data, the proportion of funding allocated to preventive care and its
allocation to health promotion and disease prevention activities was assessed. Finally,
prevention expenditure per capita and as a share of health expenditure by country in 2019 was
illustrated. It is important to note that the number of countries varies between graphs as a result
of inconsistencies within and between countries reporting preventive care expenditures.

The second phase was a discrete cross-correlation function which measures the temporal
similarity between two independent time series variables.74 Similar to the Pearson productmoment correlation coefficient, it measures the strength and direction of the relationship
between two variables.74 Often one series is shifted so that one variable lags or leads another
variable. The lag or lead that has the best alignment results in the peak cross-correlation value.74
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To illustrate, Figure 5a adapts Dean et al. (2016) description of a cross-correlation function.75 It
presents two hypothetical time series variables representing health outcomes and expenditures
over 50 observations in length. These variables have seemingly no apparent relationship. Shifting
the spending variable to the left achieves alignment by lagging health outcomes. A lag of five
time periods maximizes the pairwise correlation as shown in Figure 5b. This means that both
series increase and decrease together after five time periods, resulting in a strong positive crosscorrelation.75

Figure 5a. Two independent time series variables 75
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Figure 5b. Aligned at maximum cross-correlation, lag of 5 periods 75
Health Outcome

0

5

10

15

20

Time

Spending

25

30

35

40

45

36

This procedure was used in this analysis to estimate the time-lagged relationship between
preventive care spending and health outcomes from 2000 to 2019. A lagged association was
considered because of the period needed for prevention measures to affect the population. The
cross-correlation function examined four paired relationships between two health outcome
measures and its relationship with two preventive care expenditure measures. Health outcomes
were expressed as life expectancy (LE) and health-adjusted life expectancy (HALE). Preventive
care spending was examined as a share of GDP and as a per capita measure.

The cross-correlation function was conducted in SAS 9.4. As a result of a large number of missing
values, eight countries were not included in this analysis given the restrictions in SAS. Their
inclusion would compromise the accuracy of results due to a small sample size. The following
countries were excluded from this analysis: Chile, Colombia, Costa Rica, Israel, Ireland, New
Zealand, Turkey, and the United Kingdom. The remainder of the analysis consisted of 30 OECD
countries. Approximately 10 countries had four missing values or less, which occurred in the
beginning or end of the study period. In these cases, missing values were excluded from the
analysis.

Before conducting cross-correlation, the data is required to have stationarity and no
autocorrelation.76,77 Stationarity occurs when the mean and variance are constant over time.76,78
Autocorrelation occurs when the time series variable has an association with a lagged version of
itself. This can cause a spurious correlation between two independent time series variables.79 An
amended Box-Jenkins approach was used to estimate parameters for each variable to test and
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correct these conditions. This strategy is commonly used in time series modeling that features
the identification, estimation, and diagnostic checking of independent and dependent time
series variables. 80,81

Autocorrelation was checked using the Durbin-Watson test, which is typically used to test for
autocorrelation in time series data. The test statistic provides a value between zero and four and
the closer the value is to two, the data series is not autocorrelated.82 Results from the DurbinWatson test for the two spending measures and two health outcome measures for each country
can be found in Appendix B. Conclusions were made based on a combination test statistic’s value
being close to two with a significant p-value of .05 or less and visual inspection of the histogram
and QQ plots. All health outcome and prevention spending measures had autocorrelation. A prewhitening process is done automatically in SAS which corrects autocorrelation.

The augmented Dickey Fuller (ADF) test was used to check for stationarity.76,81 This is a
commonly used unit root test for stationarity where the alternative hypothesis suggests the
presence of stationarity. Results of the ADF test are presented in Appendix C showing the test
statistic, tau, (t) and p-value. Conclusions were based on the p-value of t and trends greater than
.05, visual inspection autocorrelation function (ACF), and partial autocorrelation function (PACF).
All variables were found to have non-stationarity.

Each variable was differenced to correct non-stationarity. Differencing removes the value from
the previous time period to obtain sequential changes in time.76,77 If the p-value of chi-square
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(X2) is greater than .05, it suggests differencing does not reject the white noise hypothesis and
the data has stationarity.80 The white noise hypothesis tests whether the autocorrelation of the
series, up to a certain number of lags, has information to model. 80 If lags are significantly
different from zero, then no further modeling is needed and suggests stationarity. Visual
inspection of the ACF, PACF and trend line was also examined to verify the results of the p-value
of X2. Approximately 28 variables needed further modeling, and all other variables resulted in
stationarity as a result of differencing. Diagnostic results presenting the p-value of X2 can be
found in Appendix D.

The Box-Jenkins approach for variable estimation was used for the time series that required
further modeling. Parameters were estimated using conditional least squares estimation to
specify autoregression (AR), moving average (MA), or combined autoregression integrated
moving average (ARIMA) model.80 An autoregression of first difference (AR1,1) was attempted. If
results were not significant, then a moving average of first difference (MA 1,1) was modeled and
compared with the AR1,1. If neither AR1,1 or MA1,1 had significant results, then ARIMA of first
or second differences was modeled. Significant results were based on 1) parameter estimate was
less than one and had a significant p-value of less than .05; 2) A small value for the Akaike’s
Information Criterion (AIC) and Bayesian Information Criterion (BIC), which suggests that the
model has a better fit; and 3) X2 p-value of .05 or greater, which rejects the white noise
hypothesis that the autocorrelation in a given lag are not significantly different from zero.80
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A summary of the parameters for each variable by country can be found in Appendix E. With
these corrections to the individual time series, the cross-correlation of preventive care spending
and health outcomes was estimated, expressed as equation 1.76
(1)

%! (&, () = *+,, (&"#! , (" )

In this equation, X represents preventive care expenditures and Y represents health outcomes.
The time lag (k) establishes the cross-correlation between X at t years before Y. Given that health
outcomes are the response variable, a negative lag and positive correlation was expected. The
cross-correlation with the greatest absolute value was selected between zero and four lags.
Thus, preventive care spending lagged health outcomes between 0 and -4 years. A four-year lag
was used as a result of a sample size of 20 periods. A lag greater than 25% of the series length
would have resulted in poor approximations in the correlation statistics. The four paired
relationships used in the cross-correlation function included:
-

HALE and preventive care expenditure per capita

-

HALE and preventive care expenditure as a share of GDP

-

LE and preventive care expenditure per capita

-

LE and preventive care expenditure as a share of GDP

Countries were grouped based on similarity of cross-correlation results. These groups were used
to further explore the constancy of the direction of cross-correlation coefficients within
countries. The groups were used to examine differences of cross-correlations between countries
using economic and demographic variables in the third phase of the analysis. The economic
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indicators included the average annual GDP growth rate per capita and the average social
protection expenditure and curative care expenditures per capita. The differences between
country grouping based on variations in health financing systems were examined. The
demographic indicators that were explored included overall population level, average rate of
change in the proportion of youth and proportion of elderly, and the Human Capital Index (HCI).
The description below provides further explanation for selecting these variables for the last part
of the analysis.

Data Description

Most health spending empirical studies use LE as a proxy for health outcomes.42,49,53,83,84 Though
it has been suggested that HALE is a better alternative than LE,42,46,47,51 HALE is a summary
measure that quantifies the expected years of life spent in good health and addresses disability
and death, allowing the measure to summarize LE with a full stock of health.43,85 It is calculated
by adjusting independent comorbidity, age, sex, and country to estimate the all-cause years lost
due to disability rate per capita.85 HALE is advantageous as an outcome measure because it is
free from the influence of population size and age structure and avoids bias of setting population
health goals. It also allows for cross comparability among countries.45 It reflects health equity to
show observable differences between countries.45 This analysis requires a measure that assesses
the length and quality of life in a country because as public health measures become more
effective, the gains in LE should reflect quality of life. LE was included in this analysis because it is
a common measure in the literature for health system efficiency, economic development, and
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well-being. It also has a strong correlation with other population health indicators and therefore
has been regarded as a good indicator for health outcomes.83 HALE from birth is available on the
Global Burden of Disease, and LE from birth was retrieved from the OECD.

Preventive care expenditure is based within the boundary of primary prevention – to avert
diseases and their risk factors, and secondary prevention – to detect diseases early. The System
of Health Accounts (SHA) accounts for preventive care spending on activities for primary and
secondary prevention at the individual and population levels.86 SHA defines preventive care as
“any measure that aims to avoid or reduce the number of the severity of injuries and diseases,
their sequelae, and complications”.86 SHA excludes tertiary prevention from preventive care
because it is assumed that is covered under curative care.86 Preventive care is further broken
down into six subcategories: information, education and counseling programs; immunizations;
early disease detection; healthy conditioning monitoring; epidemiological surveillance; and
disaster and emergency response preparation.86

Information, education, and counseling services incorporate individual- and population-level
programs. This can include mass-media campaigns, like tobacco cessation, and personal advice,
such as daily aspirin use.7 Immunization programs are vaccines that prevent the onset of
diseases across all age groups and also include immunizations for travel or tourism. Early disease
detection is related to screening for a single disease and usually targets a high-risk group, for
example, cervical cancer screening among women ages 21-65.86 Healthy condition monitoring
targets healthy individuals who can be at risk for illness. It is comprised of annual wellness visits,
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routine dental check-ups, workplace health monitoring campaigns, or antenatal check-ups. 86
Epidemiological surveillance and risk and disease control programs take into account the role of
the health system to track and monitor disease.7 This category includes information systems,
epidemiological assessments, program monitoring and evaluation, and operational research.7
Preparing for disaster and emergency response accounts for the response to human and natural
humanitarian emergencies.

Expenditure data were based on constant Purchasing Power Parity (PPP) in U.S. dollars to allow
for uniform comparisons across countries over time.87 Constant expenditures adjusts for the
effects of inflation and captures changes in volume of goods and services.87,88 PPP is expressed in
U.S. dollars and balances the purchasing power across countries by equalizing the price of the
same basket of goods and services in different countries.87,88 It uses a single base year to
eliminate differences in price levels between countries. For this analysis the base year was 2015.
Preventive care expenditures as a share of GDP and per capita are available on OECD statistics
from 2000 to 2019. Comparing health expenditures as a share of GDP between countries may
provide a distorted measure if countries experience large increases or declines in their
economies.36 Health expenditures may appear greater than they actually are if a country is
experiencing an economic decline. Preventive care expenditures per capita regards population
size and is a more accurate measure to compare health spending between countries.36 Both
measures were used in the cross-correlation function based on the literature suggesting the
incongruity between the two measures.36
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Demographic and economic variables considered for the analysis are found in Table 1, which
provides a list of the variables and rationale for including them in the model.

Table 1. Demographic and economic variables and relationship to health expenditures
Variable

Relationship

GDP

A bi-directional relationship between GDP and health spending though
previous analyses were not specific to preventive care.40,83,84

Curative Care
expenditure

Competes for the same limited resources. Increases in curative care
crowd out the available resources for preventive care.17

Social Protection
expenditure

Redistribution of income through social benefits like unemployment
benefits, pension payments, housing, etc. This type of spending has a
stronger relationship with health outcomes than health spending.53,89

Finance System

System of financing responds differently to changes in health
expenditures.42,84

Ratio of Youth in
the Population

Ambiguous relationship between age and prevention. Rapidly aging
populations affect health spending, but evidence indicates that age
increases the demand on health services.30,53,90

Ratio of Elderly in
the Population
Human Capital
Index

Proxy for workforce productivity and could be reflective of social
determinants of health in a given country.90–92

Studies indicate a positive relationship between public health expenditures per capita and GDP
as an absolute and per capita measure, suggesting the existence of bi-directional causality.83,93–95
Examining the average annual GDP per capita growth rate from 2000 to 2019 could be
meaningful given that previous studies, though not specific to preventive care, illustrate that
investment in health cultivates economic growth.31 GDP per capita for the study period are
found from the OECD.96 Other expenditures that compete for the same limited resources were
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considered. Social protection and curative care spending were examined to explore if differences
in the average per capita expenditure can be used to predict this study’s relationship of
interest.17 Given that social protection programs can address social determinants of health, we
anticipated a linear relationship between cross-correlation coefficients and social protection
expenditures. We expected an inverse, or opposite, relationship with curative care expenditures
as a result of the nonlinear association found in previous publications.17

Three types of health financing systems are recognized as multiple insurance schemes, national
health care systems, or a single-payer model. A national health system is a system in which
health providers and hospitals are publicly owned and financed with public funds in the form of
taxes.97 A multiple insurance scheme refers to a health system with multiple payers, which can
include the government and private insurance companies that are financed through premiums
paid by beneficiaries, employers, or the government.97 The single-payer model is a public or
quasi-public agency that takes responsibility for financing health services and physicians, but
hospitals are private practices. Health systems based on this model experience lower
administrative costs and spend a smaller share of the GDP on health.97,98 Previous studies have
found that financing systems show varying levels of effectiveness as it relates to health spending
and outcomes.52 A number of studies recommend including financing systems in empirical
analyses to take into account the heterogeneity of health systems between countries.42,52,84 They
suggest that different types of health systems respond differently to changes in health spending.
The Health Systems Characteristics Survey administered by the OECD has financing systems by
country that were reported in 2016.
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Because changes in health spending are affected by the size and structure of the population,99
the size of the overall population and the proportion of youth and elderly in the population were
examined. Age is a determinant to health spending because an aging demographic increases the
demand for more health services, especially in rapidly aging populations.53 However, the
relationship is ambiguous because while older individuals have less incentive to invest in health,
older individuals may demand more health services due to the depreciation of health capital
with age.30,90 This demand for health services is not specific to preventive care given that older
populations demand more long-term and rehabilitative care. But some evidence suggests that
older women seek preventive services because of the benefit from early disease detection.90
When examining these variables, the average rate of change in the proportion of youth and
elderly from 2000 to 2018 was considered. The proportion of youth and elderly in 2019 was not
available. The ratio of youth in the population is the share of 15- to 24-year-olds and the ratio of
elderly in the population is the share of 65 and older in a country. Population and ratios were
retrieved from the OECD.100

The Human Capital Index (HCI) was developed by the World Bank to quantify progress in health
and education and is used to determine how they drive economic growth.92 The index measures
child and adult survival rates and the quality and quantity of education.92 It estimates the survival
of children using mortality rates and the rate of stunting for children under age five.92 Adult
survival rate based on the fraction of 15 year-olds that survive to the age of 60.92 HCI is used for
cross country comparisons on the expected productivity of future workers. The index ranges
from 0 to 1, where 1 is equivalent to full health and completion of high-quality education. This
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indicator was explored given the reciprocal relationship human capital has on economic growth
and demand for health. Based on Grossman’s health investment theory, individuals in good
health and more education have higher productivity leading to economic growth.30 The HCI may
reflect the conditions in which the population has improved social determinants of health, given
that countries in this analysis already have advanced economies. The 2018 HCI used was
retrieved from the World Bank.92

The following provides results of the analysis and a discussion on the possible factors that
influence the relationship between preventive care spending and health outcomes. This is
followed by limitations of the analysis and conclusion.
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Results
The subsequent section presents results in three distinct phases: descriptive analysis of
preventive care expenditures, cross-correlation coefficients of the four paired relationships, and
descriptive analysis using economic and demographic indicators to explore differences between
country specific cross-correlation.

Phase 1. Descriptive Analysis

Employing expenditure data from the System of Health Accounts (SHA), a descriptive analysis of
preventive care spending was conducted. A report published by the Organization of Economic
Co-operation and Development (OECD) examining preventive care expenditures from 2005 to
2015 was used as the foundation for this part of the analysis.1 The following presents the results
of the descriptive analysis using prevention spending data from 2000 to 2019.

Trends in the growth rate of preventive care spending was much more volatile in the first half
compared to the second half of our study period. Figure 6 presents the growth rate of GDP and
preventive care and total health expenditures from 2000 to 2019. Because of the inconsistency
of countries reporting prevention expenditure data regularly, the graph represents 23 of 37
OECD countries. The growth rate in prevention was 6% among OECD countries during the Great
Recession from 2008-2009. However, there was a significant contraction following the economic
crisis. This may indicate a lagged response over time in preventive care spending as a result of a
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decline in the GDP growth rate. Despite multiple global outbreaks of infectious diseases since the
Great Recession, spending on prevention has not recovered to its pre-economic crisis growth
rate. The growth rate in prevention since 2012 have been between 2% and 3%. There has also
been a consistent gap between the growth rate of prevention and total health spending since
the Great Recession, except for a slight convergence in 2014-15.

Figure 6. GDP, preventive care, and health expenditures growth rate, in real terms, per capita
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The range of preventive care spending per capita and as a share of total health expenditures
varies widely among OECD countries in 2019, as shown in Figure 8. The graph represents 32
countries, which includes the 30 countries that reported preventive care expenditures in 2019,
plus two countries from 2018 (Australia and Japan). Examining these countries follows the
previous analysis published by the OECD using 2015 data.1 The graph represents preventive care
expenditures per capita, scaled on the left, and its share of total health spending, scaled on the
right. In the previous report, 31 countries were represented but their results are similar with this
analysis. Canada spent the most per capita on prevention and it accounts for a larger portion of
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their health funds. In 2019, Canada and the U.S. had the highest per capita expenditures at
approximately $300. This is almost three times the OECD average of $92 per capita. This
contrasts slightly from 2015 in which the OECD average was $116 per capita, and Canada and
the U.S. spent two-and-half times the OECD average.1 On average, OECD countries spend 2.2%
of total health spending on prevention. This is less than the OECD average of 2.8% reported in
2015. The share of prevention in Canada is double that of the US at 6% compared to
approximately 3%, respectively. Conversely, Hungary and Mexico spent significantly less than the
OECD average per capita at approximately $30 and preventive care accounts between 2% and
2.7% of their total health funds. These results are consistent with what was reported from 2015.

Figure 7. Prevention expenditures per capita and as a share of total health expenditure, 2019
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In 2019, 30 countries reported total spending on prevention, but only 21 countries reported by
subcategories. Most notably, Canada and the U.S., the largest spenders on prevention, did not
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% of current health expenditures
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report expenditures by subcategories. The pie chart shown in Figure 7 presents the allocation of
health expenditures to preventive care and its associated activities in 2019 representing the 21
countries. Of those countries, based on the SHA framework of total health expenditures, a total
of approximately $1.3 trillion were spent in health, of which a little over 3% were spent on
prevention. The remaining funds were directed to curative or rehabilitative care, medical goods
and devices, and health governance. Of the expenditures that were reported, a large proportion
of preventive care funds, approximately a third, is spent in health condition monitoring, which
are wellness programs like dental exams, prenatal care, and annual wellness checkups. Despite
the large benefits, less is spent on population-level programs of approximately 40% compared to
individual level clinical preventive services, spending a total of approximately 58% of preventive
care funds.

Appendix F presents the distribution of preventive care expenditures by subcategory for the 21
countries. Expenditures for the subcategories were not uniform and mostly skewed to the right
with a number of outliers over the maximum. The expenditures for information, education, and
counseling; immunization, early disease detection, and epidemiological surveillance are skewed
to the right. The median of health condition monitoring is the largest at almost $500 million.
Emergency preparedness and response was an exception because of the 21 countries that
reported preventive care expenditure subcategories, only six countries reported a value for
emergency preparedness and response. The median amount spent in that category was $5.9
million, though the maximum expenditure was $60.4 million.
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Figure 8. Proportion allocated to preventive care and associated activities in 2019
Total 2019 Health Expenditures,
$1,360,261
Millions, PPP
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Note: Data refers to OECD average for 2019 representing 21 countries. IEC is information, education, and counseling. PPP is
purchasing power parity

Phase 2. Cross-Correlation

The cross-correlation between two health outcome measures and two spending measures
resulted in the following paired relationships:
-

HALE and preventive care expenditures per capita

-

HALE and preventive care expenditures as a share of GDP

-

LE and preventive care expenditures per capita

-

LE and preventive care expenditures as a share of GDP

A strong positive association was anticipated between past government preventive care
expenditures and health outcomes. A positive cross-correlation suggests that the direction of
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health outcome and spending measure were the same. This could mean that spending and
health outcomes increased or decreased together after a period of time. Conversely, a negative
relationship suggests that health outcomes and spending change or move in opposite directions.
Cross-correlation coefficients that have a value close to 1 or -1 suggests a stronger relationship
and closer to 0 suggests a weaker relationship. The following presents the results of the crosscorrelation function for the four paired relationships.

A total of 10 countries, or a third, had positive cross-correlation across all four relationships, and
five countries, or 16%, had negative cross-correlations across all four relationships. The
remaining 15, or half of the countries, resulted in inconclusive results to show whether a
relationship exists between prevention spending and health outcomes. The time lag average and
mode were approximately two years across all relationships. Figure 9 presents the crosscorrelation between the four paired relationships by country.
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Figure 9. Cross-correlations results by country
HALE-PCECAP

HALE-PCEGDP

LE-PCECAP

LE-PCEGDP

Cross-Correlation Coefficient

0.8
0.6
0.4
0.2
0
-0.2
-0.4
-0.6

Positive

Negative

Switzerland

Inconclusive

Note: HALE is healthy-adjusted life expectancy, LE is life expectancy, PCAP is preventive care expenditures per capita, PGDP is
preventive care expenditures as a share of GDP

Table 2 presents countries grouped based on the cross-correlation results. Countries with four
positive cross-correlations were grouped together, as well as countries with four negative
relationships. The remaining countries were grouped together based on the inconclusive results
between the four paired cross-correlations. Countries with consistent strength and direction
across the four paired cross-correlations suggests that the relationships are capturing accordant
information. Countries with varying strength or direction across the four paired crosscorrelations may suggest that the relationship is capturing other information causing
inconsistent results. The distribution of the four paired cross-correlation coefficients for 30
countries are similar regarding their spread, variation, and average of the coefficients. Results for
country specific cross-correlations and their corresponding time lag can be found in Appendix G.
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United States

Sweden

Spain

Slovkia

Slovenia

Italy

Luxembourg

Greece

Germany

Denmark

Canada

Belgium

Austria

Portugal

Australia

Latvia

Norway

Japan

Poland

Estonia

Netherlands

Mexico

Lithuania

Korea

Iceland

Hungary

France

Finland

Czechia

-0.8

Table 2. Country groups
Positive

4 relationships with a
consistent positive
correlation

Czechia, Finland, France, Hungary, Iceland, Korea,
Lithuania, Mexico, Netherlands, Poland

Negative

4 relationships with a
consistent negative
correlation

Estonia, Japan, Latvia, Norway, Portugal

Inconclusive Inconsistent correlations
between the 4
relationships

Australia, Austria, Belgium, Canada, Denmark,
Germany, Greece, Italy, Luxembourg, Slovakia,
Slovenia, Spain, Switzerland, Sweden, United States

Phase 3. Between Country Differences

Economic and demographic factors were included to delineate differences in the strength or
direction of cross-correlation coefficients. Because of the possible lagged response of the decline
of prevention spending after the Great Recession, as shown in Figure 5 above, a possible
existence of a trend between the pairs of cross-correlation and GDP was investigated. We
expected lower GDP growth rates among the negative group and high annual growth rates
among the positive group. The average annual GDP per capita growth rate from 2000 to 2019
was used. The average annual GDP growth rate during the study period ranged from -0.08%
(Italy) and 5.46% (Lithuania).
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Figure 10a plots the correlations between HALE and preventive care expenditures as a share of
GDP against the average annual GDP per capita growth rate. Figure 10b plots the correlation
between LE and preventive care expenditures as a share of GDP against the average annual GDP
per capita growth rate. Both scatter plots do not indicate a discernible trend with the average
annual GDP per capita growth rate. The paired correlations with preventive care expenditures
per capita against the average annual GDP growth rate can be found in Appendix H1 and H2,
which shows similar results.

Figure 10a. Average annual GDP growth rate per capita by the cross-correlation of HALE and
preventive care spending as a share of GDP
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Note: Country acronyms can be found in Appendix A

Figure 10b. Average annual GDP growth rate per capita by the cross-correlation of LE and
preventive care spending as a share of GDP
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Other types of public spending that compete for the same limited resources as preventive care
were examined. A crowding out effect occurs between curative and preventive care.17 Based on
previous studies more funds allocated to prevention hinders progress in innovative
therapeutics.17 Spending more money in curative care weakens advancements in population
health. Therefore, an inverse relationship was anticipated between the level of curative care
spending and the cross-correlation coefficients. In 2018, on average, OECD countries spent
almost $1,900 per capita in curative care, much greater than the average $300 per capita on
prevention. However, there were no apparent differences in the level of funding for curative
care to explain differences in the paired cross-correlations within countries or between groups.

Expenditures in social protection were then examined. These types of expenditures are social
benefits like unemployment benefits, pension payments, housing allowances, etc. Because social
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protection addresses some social determinants of health, a linear relationship with the paired
cross-correlations was expected. Figure 11a plots the paired correlations of HALE and preventive
care expenditures per capita against the average social protection expenditures per capita.
Figure 11b plots the paired correlation of LE and preventive care expenditures per capita against
the average social protection expenditures per capita. The scatter plots do not indicate a
discernible relationship between the cross-correlation and average social protection expenditure
per capita. The paired correlations of health outcomes with preventive care expenditures as a
share of GDP against the average social protection expenditure per capita can be found in
Appendix I1 and I2 showing similar results.

Figure 11a. Average social protection expenditure per capita by the cross-correlation of HALE
and preventive care spending per capita
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Figure 11b. Average social protection expenditure per capita by the cross-correlation of LE and
preventive care spending as a share of GDP
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Health finance systems may also influence the coverage and financial protection in accessing
clinical preventive care services. As shown in Figure 12, of the 30 countries in the analysis, half of
the countries in the positive group had a single-payer model. Half of the countries in the
negative group have a national health system, and nearly half of the countries in the inconclusive
group had a multiple insurance scheme. These results are relative to a small sample of 30 total
countries in the analysis, which became smaller once grouped by cross-correlation coefficients,
e.g., the negative group has a total of five countries.
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Figure 12. Country Groupings by Health Finance Systems
8
7
6
5
4
3
2
1
0
Positive Correlations
Multiple insurance schemes

Negative Correlations
Inconclusive Correlations
Single-payer model
National health system

Country specific population size and structure, defined by population growth rates, and
composition, explained by the Human Capital Index (HCI), were examined. The U.S. has the
largest population size among the countries in the analysis. It is almost three times larger than
the next most populous country of Japan. Population size alone could not predict differences in
the relationship between preventive care spending and health outcomes. The average rate of
change in the proportion of elderly and youth in the population from 2000 to 2018 were
examined. Figure 13 presents the average rate of change in the proportion of youth and elderly
arranged by country cross-correlation groups. Trends across all countries show a growing elderly
population and declining population of youth from 2000 to 2018. There were no discernible
differences between groups based on the growth rates. Korea and Mexico have paced each
other in their epidemiological transition and have similar changes in their population
structures.101 The rate of change in the proportion of Korean youth is declining at a rate of -0.45,
and the proportion of Korean elderly is increasing at a rate of 0.39. The proportion of Mexican
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youth is similar to that of Korea declining at a rate of change of -0.43. However, the proportion
of Mexican elderly is steadily increasing at a rate of 0.13. Lastly, the HCI ranged from 0.61 to
0.84, with an average of 0.76. HCI did not vary significantly between countries or between
groups. No other noticeable association with HCI was identified between the four paired crosscorrelations.
Figure 13. Average Rate of Change in the Proportion of Youth and Elderly, 2000 to 2018
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Discussion
Health promotion and disease prevention activities can have large-scale implications in
advancing health equity and addressing social determinants of health. However, of the OECD
countries analyzed, the reported spending using public funds were between 2% to 3% of total
health funds on preventive care, based on the results of Figures 7 and 8. These amounts are
consistent with previous OECD-based analyses on the proportion of funds dedicated to
prevention.1,11 It appears counterintuitive to spend a relatively small portion on prevention given
the potential population-level benefits.102,103 Perhaps the lack of empirical research on
preventive care spending patterns could be the result of unreliable or unavailable health
expenditure data. This may contribute to the challenges in advocating and sustaining continued
investments in public health.16 This dissertation explored the available expenditure data related
to public health and concludes the need for better quality public health spending data. This
could support and encourage further research on public funding for prevention and its
relationship to health outcomes. The following provides a discussion on the descriptive and
cross-correlation analyses accompanied by possible explanations. This is proceeded by a review
of data quality based on the System of Health Accounts (SHA), recommendations, limitations,
and conclusions.
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Descriptive Analyses

Preventive care is comprised of a combination of population-level and individual clinical
preventive services. Based on the proportion of expenditures in health promotion and disease
prevention activities, in Figure 7, more funds were spent on individual-level clinical preventive
services than population-level programs in 2019. This is contrary to the evidence which suggests
that population-level programs have a greater impact and require less individual effort.1,102
Individual-level services include health condition monitoring (33%), immunization (13%), and
early disease detection (12%). Within clinical preventive services, 33% is spent on programs like
annual wellness check-ups, dental exams, and antenatal visits which constitute health condition
monitoring. This is a significant amount considering that these programs do not have extensive
cost-effective evidence compared to immunization and early disease detection programs.1

The scale of funding within population-based programs are equivalent to the 2015 OECD
descriptive analysis on preventive care spending.1 Population-based programs include
information, education, and counselling (23%), epidemiological surveillance (18%), and
emergency preparedness and response (0.22%). This may indicate that countries are not altering
their pattern of spending on prevention or countries are not reporting their spending on
prevention. It perpetuates a cycle of panic and neglect within public health systems. This cycle
was penned by the World Bank in 2015 about the reactionary response leaders have in attending
to the public health systems during an emergency and disregards it when the urgency fades.104
Though this was stated in the context of emergency preparedness and response, a resilient
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public health system is necessary to continually safeguard the public. Ending this cycle requires
additional evidence that aligns the benefits, both human and economic, with the investments
made by the public. The literature provides some limited evidence showing the economic
returns from investing in public health.32,58 Even less is published on the impact on health
outcomes or quality of life as a result of changes in the level of spending for preventive care.105
This work adds to the evidence base by presenting results of a cross-correlation function of four
paired relationships between health outcomes and preventive care spending. These results
incorporate descriptive analyses to provide an explanation and possible implications.

A third of countries in the analysis had positive cross-correlations across the four relationships
after a lag of approximately two to three years. A positive cross-correlation suggests that
spending on prevention and health outcomes move in the same direction after a period of time.
Policy makers may find these results useful when faced with budget reductions as a result of an
economic crisis or a human or natural emergency. It is important to note that the strength of the
correlation may vary between the four paired relationships even though they have the same
direction. The variation in strength within countries may denote a spurious conclusion in
examining a lag between zero and four as a result of 20 time periods for a time series analysis. It
would be important to test if changes in the timescale match these results.

Five out of 10 countries in the positive group had a single-payer financing system model. Though
the sample size is small, previous research suggests that health systems based on this model
experience lower administrative costs, spend a smaller share of the GDP on health, and cover a
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larger portion of the population.98 Compared to countries with a multiple insurance scheme and
national health systems, countries with a single-payer model have also been found to have
greater perceived health status.84 Because of these benefits, advocates of a single-payer model
have campaigned for it to be part of healthcare reform in the U.S.97 More research can be done
within the context of health systems to determine the effect size between preventive care
expenditures and health outcomes.17 A Granger causality model can test whether there are
lagged and repeated patterns between preventive care expenditures and health outcomes over
time within the context of a single-payer systems.106 This may provide evidence of a predictive
relationship of preventive care spending with future health outcomes. Differences in preventive
care expenditures between countries in the context of their finance systems can be meaningful.
A fixed effects model could be used to explain the variation in spending as a function of the
financing system, controlling for the utilization rates for clinical preventive services.42 It can
highlight variation in the cost to provide clinical preventive services and differences in screening
and vaccination rates. Results could drive future studies examining the context in which a
financing system reduces financial barriers and lowers costs for preventive care services.

The countries with four negative cross-correlation coefficients describe the extent that health
outcomes and preventive care expenditures move in opposite directions. A ceiling effect could
play a role in these results. Spending on prevention alone may not be sufficient to improve
health outcomes. The systems, policies, and practices in place may have a reciprocal effect in
reducing financial barriers, strengthening equitable allocation of resources, and improving access
to preventive care services. From Figure 7 in 2019, compared to other OECD countries, Canada
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and the U.S. spent the largest amount per capita of approximately $300. Both Canada and the
U.S. were in the inconclusive group. Further research is needed on efficiencies in spending to
improve performance in adhering to policies and practices and service delivery.107 Funding
allocation practices, like performance-based strategies or optimization- and formula-based
models, may have implications in the equitable distribution of funds by targeting hard-to-reach
and vulnerable populations.107 The differences between countries may also call for a closer
investigation on the type of approaches used for preventive service delivery. Though clinical
preventive services is more prohibitive because it has higher individual effort, population-based
approaches to deliver these services can have a large impact.102 These approaches are strategies
to reach and manage patients regardless of the distribution of risk for a disease or
condition.102 For example, using a population-based approach to screen for high blood pressure,
which is usually asymptomatic, can improve quality of life and reduce the likelihood of
experiencing a cardiovascular event.102 Alternatively, opportunistic-based approaches leave the
initiation of clinical preventive services to the individual.1 Evidence of screening rates from highincome countries suggest that those with population-based screening programs are more
effective in reaching those with lower socioeconomic status.1 The nuances of the policies and
practices to distribute funds and the strategies in which funds are used can provide more insight
on the efficiencies of funds allocated to preventive care.

Countries with negative cross-correlations were contrary to the expected hypothesis of this
study. These results could be the result of insufficient time periods in examining lags of more
than four periods. It could also point to the lack of consistent reporting by countries in conveying
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their true spending in prevention. Alternatively, it may suggest that governments are ill-informed
of public health impact. Reinvestment rarely happens as a result of a successful public health
action. This is known as the “wrong pocket” problem.105 It occurs when a public health program
is successful, but it does not gain the savings that accompany improvements in health, and the
benefits are likely enjoyed by another sector. For example, an infectious disease outbreak
investigation prevents exposure to an infected individual, or a tobacco cessation campaign helps
individuals stop smoking. These public health actions avert thousands of dollars in medical or
hospitalization bills, typically paid by the individual and/or healthcare payer/insurer. Though
public funds may finance the prevention activity, the costs averted may benefit another entity,
i.e., the accrued savings goes into the “wrong pocket.”105 Without knowing the true populationlevel benefits, including savings, of prevention spending, decision makers are not fully informed
about the value of public health. The lack of information on the value of prevention spending is
likely to result in chronic underfunding based on systemic undervaluing of public health impact.73

Half of the countries in this analysis had inconclusive cross-correlations and did not support this
dissertation’s hypothesis of four positive cross-correlation coefficients. Similar to the countries
with four negative cross-correlations, these results could be due to limited timeseries or
variability and inaccurate reporting in preventive care funding levels. As shown in Figure 5, the
growth rate of preventive care fluctuated in the early part of the study period, and it did not
recover after the Great Recession. This signals that the inability to sustain predictable funding
levels overtime may have contributed to the inconclusive results. Given that on average 3% of
total health spending is allocated to prevention among OECD countries, it is also possible that a
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larger proportion of funds is needed to have an effect on health outcomes. Currently, there are
no formal recommendations for an optimal funding level. Without robust investigations on
spending patterns in preventive care, it is difficult to know the optimal or minimum funding level
at which public health can thrive. As a result, it presents challenges to advocate for predictable
funding levels and, therefore, difficult to maintain a resilient public health system. The
inconclusive cross-correlations could be related to the allocation of funds to programs like health
condition monitoring in which cost-effective evidence is absent.1 Health condition monitoring
accounts for a large proportion (33%) of an already small fraction of total health spending. The
opportunity cost in programs like these make it hard to justify continued investment in public
health. Allocating resources to programs that lack sufficient evidence on their effectiveness can
potentially overburden the health system, and impose the possibility for duplicative tests, overdiagnosis, and waste.108

The extensive connection between health outcomes and socioeconomic factors, or social
determinants of health3, could reflect the study’s findings of either a negative or inconclusive
cross-correlation. The System of Health Accounts (SHA) defines preventive care as health
promotion or early disease detection activities where the primary purpose of those activities is
health.7 The prevailing definition of prevention addresses social determinants of health which
inherently partners across sectors, like education, planning, housing, and labor sectors.3 Defining
it through the traditional sense does not account for multisectoral collaboration that could
contribute to improvements in overall health outcomes. Failing to account for expenditures that
support social factors underestimates the depth of public health research and practice.
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Examining funds allocated to preventive care in conjunction with funding associated with
programs that address social determinants of health may be the critical force that drives
improvements in health. However, extracting funding levels or determining sources of funds can
be overly complicated and difficult to collect from multiple stakeholders. Additionally, the SHA’s
definition of prevention underestimates the amount spent and its impact by not accounting for
public health regulatory and fiscal activities. It does not include the cost of certain regulatory
activities, like road safety or the costs to implement a sin tax - a tax on unhealthy products. This
constrained perspective of preventive care could be another reason why research in this area is
so limited. Measuring the full extent of public health prevention expenditures and their impact
could help justify the need for sustained and predictable funding.

Review of the System of Health Accounts

The SHA was first developed in 2000 but was updated in 2011. The revisions included
reclassification of preventive care and the provision of supplemental guidance on the definitions
and boundaries to account for preventive care expenditures.109 Table 3 presents the SHA
classification of preventive care services and programs. Though the supplementary guidance
addressed ambiguities that were present in the updated 2011 revisions, uncertainties remain in
accurately reporting preventive care expenditures. The guidance does not provide examples of
activities on what constitutes preparing for disasters and emergency response (HC.6.6). Since
2011, on average, eight of 38 countries consistently reported expenditures in this category. The
credibility of those that report disaster preparedness and emergency response is questioned
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given that guidance is lacking. Without a clear distinction, expenditures for the category remain
unreported or lack credibility. This public health activity is particularly relevant in assessing the
funding levels countries appropriated and their ability to effectively respond to SARS-COV-2 and
its variants. In theory, providing guidance on what constitutes emergency preparedness may
help sustain financing at the country level and support the global community to prepare for the
next natural or human emergency.

Table 3. Classification of preventive care expenditures1
Health Care Classification

HC.6.1
HC.6.2
HC.6.3
HC.6.4
HC.6.5
HC.6.6

Preventive Care Program

Information, education, and counselling programs
Immunization programs
Early disease detection programs
Healthy condition monitoring programs
Epidemiological surveillance and risk and disease control programs
Preparing for disaster and emergency response

The category epidemiological surveillance and risk and disease control programs (HC.6.5) acts as
a catch-all for any type of system or data collecting mechanism that analyzes disease risk and
trends. It can include the planning, monitoring, and evaluation of interventions; public health
surveillance systems; health service management systems; monitoring samples of drinking water
and food; or epidemiological assessment studies.109 Aggregating the expenditures of these
systems, studies, and programs into a single category clouds the level of funding that was
invested. Investments in epidemiological surveillance is of particular relevance given that health
systems globally were ineffective in responding to COVID-19.110 Systems were neither integrated
nor interoperable with other data systems, and the workforce was not sufficiently trained to

70

manage and use health data.110 Without knowing the level of expenditures, it veils the gap in
funding to strengthen public health information systems. Aligning the SHA’s definition of
epidemiological surveillance with the World Health Organization’s (WHO) SCORE technical
package can guide the boundary for this category.111 The technical package is a comprehensive
set of strategies and interventions for country health information systems. It can be a path to
disaggregate epidemiological surveillance and risk and disease control programs and determine
their cost boundaries.

Though OECD countries report expenditure data, their reliability and credibility are subject to
scrutiny. Out of 38 OECD countries, only 23 countries consistently reported preventive care
expenditures from 2000 to 2019. In 2019, 21 countries reported the amount spent on health
promotion and disease prevention activities and the number of countries that report by activity
vary over time. Countries may not be able to report total spending on prevention or by activity
because their health systems or funding streams may be too complex to report according to the
SHA framework. The public health care sector and public health services are indistinguishable in
countries that are financed through a national health system.11 Alternatively, countries may
define public health differently from the SHA framework. This may result in large discrepancies
between national and internationally reported data.11 Inconsistency in reporting expenditure
data obscures the interpretation of public health spending measures, either as a share of GDP or
per capita, and obscures cross-country comparisons. Irregular reporting complicates the ability
to measure sustainability of public health and could perpetuate a culture of panic and neglect of
the public health system.104
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Recommendations

Results from this analysis drive the need for improvements in the quality of public health
expenditure data. A recommendation is to establish a basic standard for public health for the
purposes of securing sustained and predictable funding. This has been a recommendation from
many public health leaders but have received little traction for implementation.112,113 These
programs can be extended to include population-based programs as well as clinical preventive
services for both noncommunicable and infectious diseases. It can act as a benchmark to ensure
a basic standard for public health is met and consistently measured to reliably delineate
differences between health systems and public health services. It could offer details and
examples on what constitutes public health activities. Similar to the U.S. Preventive Services Task
Force (USPSTF), an independent voluntary panel of experts could be convened to recommend
core programs and services inclusive of social determinants of health.114 An independent panel
of global public health experts could achieve consensus on consistent guidance on core and/or
minimum level of public health programs for every country. WHO and its regional affiliates are
the likely agencies to convene global experts to establish a standard for public health given their
role as arbiters in norm and best practices.115 WHO does not have the authority to enforce
uptake and implementation, but the regional affiliates and other global partners could provide
the political and technical support for implementation.116 Any global standard should exercise
progressive elaboration which uses results from on-the-ground implementation and empirical
research to improve guidelines and standards in an iterative process. This could usher in more
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cost-effectiveness studies from diverse countries and establish an evidence base to inform
decision making for public health funding. But for this to occur, researchers would need to rely
on credible and reliable spending data. Otherwise, future research results on preventive care
puts will be of questionable validity. These data quality problems will likely contribute to
extending and exacerbating the likelihood of prolonged chronic underfunding in public
health.71,117,118

The economic and demographic variables used to assess differences between countries and
groups did not prove to have any discernible patterns with the correlations between health
outcomes and preventive care spending. This could be the result of poor-quality data or because
the sample of countries in the analysis were demographically and economically similar. OECD
countries are mostly high-income with similar population structure, like increasing rates of
elderly and declining rates of youth, and composition, including education and socioeconomic
status. These countries are also comparable in their capacity as strong fiscal stewards.11 This
alludes to the importance of reporting and monitoring expenditure data from countries that are
less homogeneous. Expenditure data from OECD countries are typically used in studies because
it is open, easily accessible, and regularly updated. Currently, health expenditure data for lowand middle-income countries are not comparable between countries or easily retrievable, and
are inaccessible, or outdated. Given that prioritizing public health cultivates workforce
productivity and economic growth, reliable and available health expenditure data from low- and
middle-income countries can advance economic development.31 It could be used to improve
efficiencies for the limited resources allocated to public health to improve the precision in
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decision-making to target vulnerable populations and to achieve greater value. A
recommendation from these results is for organizations, like WHO or the OECD, to provide
technical assistance to build global capacity to report and monitor public health spending data.
These organizations can facilitate technical assistance and have the capacity and infrastructure
to host digital data. Countries could establish policies that strengthen infrastructure and
workforce capacities to ensure that systems are interoperable.110 Establishing a data governance
framework is a mechanism to collect, manage, and disseminate consistent and complete data
from different data providers in a centralized and coordinated way.110 There have been calls for
this mechanism to facilitate national and global data comparisons for epidemiological data but
can be easily translated to expenditure data.110

Creating a culture of making expenditure data available, reliable, and credible in low-and middleincome countries can lead to meaningful policies and strategies in transitioning away from
development assistance in health (DAH). DAH are financial and in-kind contributions from donor
organizations to low- and middle-income countries.119 From 2000 to 2019 DAH ballooned over
30% from $12.4 billion to $40.6 billion.119 Countries depend on these funds to improve health
systems, prevent and control specific diseases, and contribute in funding the gap in transnational
global functions.120 As low- and middle-income countries experience economic growth, they are
eligible to transition away from DAH and depend on domestic sources of funds.119 Selfdependency allows low- and middle-income countries to set health priorities and allocate funds
based on their specific needs and context. However, without strong financing systems in place
and aligning expenditures with health outcomes, population-level inequities and inequalities can
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be exacerbated. Individuals are forced to pay out-of-pocket for health services, which may be of
poor quality, and this can lead to catastrophic household health spending and eventually affect
economic progress.119 Health expenditure data that is easily available and accessible can be used
to reveal spending patterns and inform policymakers how best to allocate scarce resources for
greater public health impact. This can contribute to making countries’ health systems more
robust and lead to greater self-sufficiency, ideally contributing to improved health coverage for
all.

Limitations

There are limitations to recognize as part of this analysis. The sample size of the time series is a
key limitation. It may also have resulted in spurious findings and possibly a reason for
inconclusive results from the cross-correlation function. The time series was 20 years of data,
which may not be sufficient for governments to make changes in the level of preventive care
spending and for those changes to impact health outcomes. Because of the limited time series,
the cross-correlation was not estimated beyond four lags to avoid poor approximations of the
correlation coefficients. The decision to study four lags was a result of the small sample size to
avoid the risk of minimizing the time series further. Longer lags, beyond four resulted in, at
times, greater absolute results or a change in direction. For example, Italy had inconclusive
results with two negative correlations and two positive correlations. If eight lags were used, all
four correlations would have been positive. A lag of eight means that changes in health
outcomes occur eight years after a change in preventive care expenditures. However, this
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further reduces the values across the time series and forces the correlation on a smaller set of
values.

The sample of countries that report expenditure data is another limitation. There are 38 member
countries in the OECD, but only 30 countries reported total preventive care expenditures from
2000 to 2019. Of those countries, 10 had missing values during the study period, which
truncated the time series and the available data for analysis. The number of countries that
reported by prevention activities was much less than those that reported total prevention
expenditures. In 2019, 21 of 38 countries reported the amount spent on health promotion and
disease prevention activities. The countries that do not report activity level data may introduce
bias as illustrated by a difference from 3% to 2% in the average preventive care expenditure,
shown in Figure 6 and 7. This indicates that the countries that did not report by activity (Figure 6)
are significant enough to reduce the average by 1%. Also, the lack of a clear definition of what
constitutes preventive care subcategories resulted in a limited number of countries to report
expenditures for emergency preparedness and response. This may have allowed for systemic
bias which could distort cross-country comparisons for the descriptive analysis. Any missing
value may indicate that definitional issues for preventive care exist, it does not necessarily mean
that funds were not spent in a preventive care activity. A missing value could mean that funds
were spent but not reported. This could suggest a possible overall underestimate in countryspecific and average amount allocated to preventive care. Because of these limitations, the data
are too noisy for aggregate and category empirical analysis which further adds to the need to
improve the quality of expenditure data reported by OECD countries.
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Another possible limitation occurred in the selection of ARIMA models during the data cleaning
phase before running the cross-correlation function. ARIMA models were selected based on a
commonly used diagnostic approach of p-values of corresponding statistics and visual inspection
of graphs like the QQ plot and histogram. Diagnostic results were not always definitive and called
for a combination of using a commonly used diagnostic approaches and knowledge of the data
to make the best judgement. The selection of another ARIMA model may have changed the
strength of the correlation but may not have changed the direction of the coefficient. Thereby
estimating the parameters of a variable as an ARIMA (0,1,1) instead of as an ARIMA (1,1,0), it
may have marginally altered the strength to be closer or farther to 1 or -1, but the direction
would have stayed consistent.

Conclusion

This dissertation provided the opportunity to explore the relationship between preventive care
expenditures and health outcomes to assess the extent to which public funds improve health
outcomes. However, as a result of conducting the analysis, this dissertation could not make a
definitive relationship due to expenditure data lacking reliability, credibility, availability, and
accessibility. Improving the quality of expenditure data can be measured against health
outcomes to ensure the sustainability of a health system. It can be used to assess the extent to
which the population has access to high-quality and low-cost health care without having to pay
catastrophic out-of-pocket expenses. Governments have the opportunity to harness the social
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and economic deficits exposed by the current pandemic to invest in and improve population
health and strengthen fiscal accountability.

Results of the cross-correlation and possible explanation presented through the descriptive
analysis can be used as the underpinning to further explore the association between
expenditures in disease prevention and health promotion with health outcomes. Without
sustained and predictable funding, it will be challenging to study the relationship between
preventive care spending and health outcomes. It is also important to understand the nuances of
policies and practices to ensure an equitable distribution and fiscal stewardship of public funds.
Variation between financing systems could offer financial protection, which may lower barriers
in accessing clinical preventive services. Having expenditure data from economic and
geographically diverse countries can support cross-country analysis.

Two recommendations are products of this analysis. First, establish a global expert group to gain
consensus on a basic standard for public health programs. Inconsistent funding levels have led to
a fragmented public health infrastructure and the current funding mechanisms.112 Without a
minimum or basic standard, it is the budget that dictates the services or programs offered to the
public.112 By establishing a comparable benchmark, countries could determine funding gaps
wherever deficits exist. The second recommendation is for multi-lateral institutions like the
OECD or WHO to provide technical assistance to low- and middle-income countries to regularly
report public health spending. These institutions also have the infrastructure and the capacity to
publicly host the data. These results and recommendations can initiate improvements in the

78

reliability, credibility, availability, and accessibility of public health expenditure data. This could
lead to further analysis which may provide economic justification for sustained and predictable
funding for public health. Additional research showing support for economic development and
growth outcomes associated with prevention spending may serve to support policy makers in
making better informed allocation decisions and spending targets consistent with improving
health outcomes.

Relative to the growth rate of GDP and total health spending, the consistent low growth rate in
prevention since 2010 demonstrates chronic underfunding of public health. The volatility in the
preventive care spending per capita illustrates the cycle of panic and neglect in public health.104
In the face of a public health emergency, governments take a reactionary response by allocating
a significant amount of resources until a new headline takes interest.104 New calls for a sustained
level and positive growth rate for public health funding have resonated across the U.S. and
globally as the COVID-19 pandemic highlighted the alarming inadequacies of public health
systems.69 DeSalvo and colleagues (2019) estimated that $4.5 billion per year is required to
adequately carry out public health activities in the U.S.18 Perhaps the economic and personal toll
of the COVID-19 pandemic, especially in high-income countries, will break the cycle of panic and
neglect. Beyond having a dedicated funding stream, it is critical to develop policies that will
allocate funds to programs equitably, improve systems, and strengthen the workforce for a more
sustainable public health system.
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Appendix
Appendix A. Country Codes
Code
AUS
AUT
CAN
CRI
CZE
DNK
EST
FIN
FRA
DEU
GRC
HUN
ISL
IRL
ITA
JPN
KOR
LVA
LTU
LUX
MEX
NLD
NOR
POL
PRT
SVK
SVN
ESP
SWE
CHE
GBR
USA

Country
Australia
Austria
Canada
Costa Rica
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Japan
Korea
Latvia
Lithuania
Luxembourg
Mexico
Netherlands
Norway
Poland
Portugal
Slovakia
Slovenia
Spain
Sweden
Switzerland
United Kingdom
United States
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Appendix B. Durbin-Watson test statistic and p-value
Country

PGDP

Conclusion

PCAP

Conclusion

HALE

Conclusion

LE

Conclusion

Australia

0.445,
<.0001
0.283,
<.0001
1.122,
0.0257
0.495,
<.0001
0.398,
<.0001
0.518,
<.0001
0.336,
<.0001
0.176,
<.0001
1.849,
0.3653
0.252,
<.0001
0.836,
0.0033
0.242,
<.0001
0.49,
<.0001
0.126,
<.0001
0.102,
<.0001

autocorrelation

0.184,
<.0001
0.134,
<.0001
0.981,
0.0105
0.123,
<.0001
0.215,
<.0001
0.288,
<.0001
0.163,
<.0001
0.162,
<.0001
1.508,
0.1279
0.073,
<.0001
0.786,
0.0021
0.357,
<.0001
0.361,
<.0001
0.126,
<.0001
0.068,
<.0001

autocorrelation

0.040,
<.0001
0.033,
<.0001
0.049,
<.0001
0.042,
<.0001
0.038,
<.0001
0.028,
<.0001
0.040,
<.0001
0.029,
<.0001
0.035,
<.0001
0.046,
<.0001
0.067,
<.0001
0.040,
<.0001
0.032,
<.0001
0.035,
<.0001
0.046,
<.0001

autocorrelation

0.044,
<.0001
0.070,
<.0001
0.120,
<.0001
0.030,
<.0001
0.043,
<.0001
0.041,
<.0001
0.036,
<.0001
0.043,
<.0001
0.074,
<.0001
0.091,
<.0001
0.156,
<.0001
0.053,
<.0001
0.274,
<.0001
0.105,
<.0001
0.069,
<.0001

autocorrelation

Austria
Belgium
Canada
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Italy
Japan

autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation

autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation

autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation

autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation

Korea
Latvia
Lithuania
Luxembourg
Mexico
Netherlands
Norway
Poland
Portugal
Slovakia
Slovenia
Spain
Sweden
Switzerland
United
States

0.077,
<.0001
1.407,
0.1074
0.433,
<.0001
0.770,
0.0008
0.440,
<.0001
0.344,
<.0001
0.282,
<.0001
0.743,
<0.0010
0.157,
<.0001
0.603,
0.0001
0.756,
0.0012
0.325,
<.001
0.273,
<.0001
0.816,
0.0014
0.588,
<.0001

autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation

0.057,
<.0001
1.006,
0.0146
0.248,
<.0001
0.700,
0.0004
0.348,
<.0001
0.347,
<.0001
0.133,
<.0001
0.902,
0.0047
0.199,
<.001
0.557,
<.0001
0.954,
0.0072
0.297,
<.0001
0.118,
<.0001
0.851,
0.0020
0.143,
<.0001

autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation

0.030,
<.0001
0.067,
<.0001
0.101,
<.0001
0.031,
<.0001
0.350,
<.0001
0.036,
<.0001
0.050,
<.0001
0.040,
<.0001
0.030,
<.0001
0.040,
<.0001
0.048,
<.0001
0.032,
<.0001
0.035,
<.0001
0.035,
<.0001
0.099,
<.0001

autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation

0.032,
<.0001
0.070,
<.0001
0.099,
<.0001
0.082,
<.0001
0.642,
0.0002
0.042,
<.0001
0.057,
<.0001
0.059,
<.0001
0.057.,
<.0001
0.045,
<.0001
0.072,
<.0001
0.072,
<.0001
0.066,
<.0001
0.066,
<.0001
0.070,
<.0001

autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation
autocorrelation

Note: PGDP is the preventive care expenditure as a proportion of GDP, PCAP is the preventive care expenditure per capita, HALE is the health adjusted life
expectancy, and LE is life expectancy.
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Appendix C. Augmented Dickey-Fuller results (t, p-value)
Country

Australia
Austria
Belgium
Canada
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Italy
Japan

PCEGDP

Conclusion

PCECAP

Conclusion

HALE

Conclusion

LE

Conclusion

-1.20,
0.6516
-2.92,
0.0619
-2.38,
0.1619
-2.84,
0.0708
-1.55,
0.4874
-1.73,
0.4014
-0.15,
0.9296
-1.21,
0.6476
-3.81,
0.0104
-1.26,
0.6244
-2.14,
0.2322
-0.82,
0.7904
-2.76,
0.0822
-0.36,
0.8982
0.04,
0.9504

nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity*
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity

-0.53,
0.8627
-2.65,
0.1004
2.25,
0.1992
-1.85,
0.3458
-1.02,
0.7240
-0.70,
0.8229
0.60,
0.9856
-1.07,
0.7068
-3.41,
0.0235
0.3,
0.9715
-1.94,
0.3073
-1.45,
0.5354
-2.59,
0.1118
-0.04,
0.9430
0.83,
0.9915

nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity*
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity

-4.35,
0.0034
-2.30,
0.1813
-1.20,
0.6508
-3.86,
0.0095
-1.15,
0.6747
-2.03,
0.2730
-1.28,
0.6151
-2.18,
0.2195
-2.35,
0.1681
-3.30,
0.0297
-2.11,
0.2444
-1.64,
0.4466
-2.11,
0.2440
-3.41,
0.0238
-1.33,
0.5942

nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity

-5.14,
0.0007
-1.53,
0.4950
-0.80,
07960
-3.24,
0.0333
-0.95,
0.7491
-0.47,
0.8779
-0.51,
0.8696
-1.48,
0.5198
-1.31,
0.6048
-1.46,
0.5333
-1.38,
0.5706
-1.17,
0.6665
-2.11,
0.2410
-0.87,
0.7748
-0.84,
0.7844

nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity

Korea
Latvia
Lithuania
Luxembourg
Mexico
Netherlands
Norway
Poland
Portugal
Slovakia
Slovenia
Spain
Sweden
Switzerland
United
States

-0.34,
0.9017
-2.90,
0.0688
-0.01,
0.9427
-2.38,
0.1610
-3.13,
0.0414
-0.66,
0.8349
-1.07,
0.7029
-3.49,
0.0217
-0.73,
0.8171
-2.24,
0.1990
-1.97,
0.2966
-2.50,
0.1316
-0.98,
0.7378
-1.74,
0.3985
-2.50,
0.1300

nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity

0.45,
0.9797
-2.32,
0.1796
1.26,
0.9967
-2.43,
0.1465
-2.96,
0.0572
-1.23,
0.6387
-1.17,
0.6610
-2.39,
0.1593
-1.02,
0.7252
-2.22,
0.2050
-2.17,
0.2248
-2.44,
0.1448
-0.48,
0.8742
-2.73,
0.0868
-2.20,
0.2132

nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity

-6.59,
<.0001
-0.15,
09295
0.51,
0.9825
-3.24,
0.0330
-2.90,
0.0639
-4.12,
0.0055
-2.22,
0.2077
-1.90,
0.3247
-3.58,
0.0170
-0.56,
0.8584
-1.22,
0.6445
-3.01,
0.0520
-3.92,
0.0084
-3.84,
0.0099
-1.77,
0.3828

nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity

-1.78,
0.3795
-0.50,
0.8696
0.88,
0.9927
-0.83,
0.7887
-2.21,
0.2096
-1.53,
0.4957
-1.13,
0.6808
-1.34,
0.5882
-1.24,
0.6333
0.06,
0.9532
-1.03,
0.7200
-0.98,
0.7394
-0.24,
0.9175
-1.52,
0.5013
-2.19,
0.2152

nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity
nonstationarity

Note: PGDP is the preventive care expenditure as a proportion of GDP, PCAP is the preventive care expenditure per capita, HALE is the health adjusted life
expectancy, and LE is life expectancy. * Denotes that the p-value is significant and suggests stationarity but will treat variables as non-stationarity to be
consistent with other variables in the analysis
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Appendix D. Diagnostics results from differencing (p-value of X2)
Country

PCEGDP

Conclusion

PCECAP

Conclusion

HALE

Conclusion

LE

Conclusion

Australia
Austria
Belgium
Canada
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary

0.1652
0.9408
0.6162
0.0141*
0.291
0.8267
0.7691
0.5661
0.1753
0.3093
0.4811
0.9927

Stationarity
stationarity
stationarity
non-stationarity
stationarity
stationarity
stationarity
stationarity
stationarity
stationarity
stationarity
stationarity

0.1493
0.6034*
0.5423
0.013*
0.174
0.9445
0.3326
0.3413
0.1492
0.0763*
0.5471
0.8439

stationarity
non-stationarity
stationarity
non-stationarity
stationarity
stationarity
stationarity
stationarity
stationarity
stationarity
stationarity
stationarity

0.034*
0.9035
0.6613
0.001*
0.8702
0.0223*
0.7938
0.1134
0.8943
0.4318
0.5814
0.805

non-stationarity
stationarity
stationarity
non-stationarity
stationarity
non-stationarity
stationarity
stationarity
stationarity
stationarity
stationarity
stationarity

0.031*
0.4418
0.0473*
0.0375*
0.5161
0.2083
0.8576
0.1962
0.658
0.3554*
0.0339*
0.11

non-stationarity
stationarity
non-stationarity
non-stationarity
stationarity
stationarity
stationarity
stationarity
stationarity
non-stationarity
non-stationarity
stationarity

Iceland
Italy
Japan
Korea

0.9972
0.8808
0.3959
0.3427

stationarity
stationarity
stationarity
stationarity

0.9926
0.5651
0.4872
0.274

stationarity
stationarity
stationarity
stationarity

0.837
0.3326
0.6522
0.0015*

stationarity
stationarity
stationarity
non-stationarity

0.2712
0.1093*
0.4498
0.8326

stationarity
non-stationarity
stationarity
stationarity

Latvia
Lithuania
Luxembourg
Mexico
Netherlands
Norway
Poland
Portugal
Slovakia
Slovenia

0.3184
0.33
0.4279
0.9533
0.8938
0.4961
0.9821
0.2703
0.8251*
0.3712*

stationarity
stationarity
stationarity
stationarity
stationarity
stationarity
stationarity
stationarity
non-stationarity
non-stationarity

0.4214
0.9093
0.5202
0.9425
0.9623
0.9321
0.9562
0.2992
0.8066*
0.3912

stationarity
stationarity
stationarity
stationarity
stationarity
stationarity
stationarity
stationarity
non-stationarity
stationarity

0.3359
0.8025
0.5234
0.8543
<.0001*
0.0809
0.359
0.0344*
0.0701*
0.8629

stationarity
stationarity
stationarity
stationarity
non-stationarity
stationarity
stationarity
non-stationarity
non-stationarity
stationarity

0.4927
0.7167
0.4899
0.6762
0.7275
0.6129
0.845
0.1663
0.0754*
0.0024*

stationarity
stationarity
stationarity
stationarity
stationarity
stationarity
stationarity
stationarity
non-stationarity
non-stationarity

Spain
Sweden
Switzerland
United States

0.7626
0.3435
0.3512
0.0121*

stationarity
stationarity
stationarity
non-stationarity

0.9148*
0.1766*
0.2709
0.0166*

non-stationarity
non-stationarity
stationarity
non-stationarity

0.0331
0.0655*
0.1001
0.0036*

non-stationarity
non-stationarity
stationarity
non-stationarity

0.3631
0.2147
0.1366
0.1348

stationarity
stationarity
stationarity
stationarity

Note: PGDP is the preventive care expenditure as a proportion of GDP, PCAP is the preventive care expenditure per capita, HALE is the health adjusted life
expectancy, and LE is life expectancy. *Denotes further modeling was necessary as a result of visual inspection of ACF and PACF.
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Appendix E. Summary of variable parameters by country
Country
PCEGDP
PCECAP
Australia
Difference
Difference
Austria
Difference
ARIMA (1,1,0)
Belgium
Difference
Difference
Canada
ARIMA (1,1,1)
ARIMA (1,1,1)
Czechia
Difference
Difference
Denmark
Difference
Difference
Estonia
Difference
Difference
Finland
Difference
Difference
France
Difference
Difference
Germany
Difference
ARIMA (0,1,1)
Greece
Difference
Difference
Hungary
Difference
Difference
Iceland
Difference
Difference
Italy
Difference
Difference
Japan
Difference
Difference
Korea
Difference
Difference
Latvia
Difference
Difference
Lithuania
Difference
Difference
Luxembourg
Difference
Difference
Mexico
Difference
Difference
Netherlands
Difference
Difference
Norway
Difference
Difference
Poland
Difference
Difference
Portugal
Difference
Difference
Slovakia
ARIMA (0,1,1)
ARIMA (0,1,1)
Slovenia
ARIMA (1,1,0)
Difference
Spain
Difference
Difference
Sweden
Difference
ARIMA (0,1,1)
Switzerland
Difference
Difference
United States
ARIMA (1,1,0)
ARIMA (0,1,1)

HALE

LE

ARRIMA (1,1,0)
Difference
Difference
ARIMA (1,1,0)
Difference
MA (1,1)
Difference
Difference
Difference
Difference
Difference
Difference
Difference
Difference
Difference
ARIMA (0,1,2)
Difference
Difference
Difference
Difference
ARMA (0,1,1)
Difference
Difference
ARIMA (1,1,0)
ARIMA (0,1,2)
Difference
ARIMA (0,1,1)
ARIMA (1,1,0)
Difference
ARIMA (1,1,0)

ARIMA (1,1,0)
ARIMA (0,1,1)
ARIMA (0,1,1)
ARIMA (1,1,0)
Difference
Difference
Difference
Difference
Difference
ARIMA (1,1,0)
ARIMA (0,1,1)
Difference
Difference
ARIMA (1,1,0)
Difference
Difference
Difference
Difference
Difference
Difference
Difference
Difference
Difference
Difference
ARIMA (0,1,2)
ARIMA (1,1,0)
ARIMA (0,1,1)
Difference
Difference
Difference

Note: PGDP is the preventive care expenditure as a proportion of GDP, PCAP is the preventive care expenditure per capita,
HALE is the health adjusted life expectancy, and LE is life expectancy
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Appendix F. Distribution of Preventive Care Funds by Category of 21 OECD Countries, 2019
5000.00
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Appendix G. Summary of cross-correlation measures by country
Country
HALE_PCAP Lag HALE_PGDP Lag LE_PCAP Lag LE_PGDP Lag
Australia
-0.5300
0
-0.5589
0
0.0989
-4
0.2115
-4
Austria
0.3232 -3
0.3921 -3
0.5451
-3 -0.4436
-2
Belgium
-0.5630 -2
0.5328 -2
-0.2514
-2 -0.2025
-2
Canada
-0.2465
0
-0.2040
0
-0.2303
0
0.3013
-3
Czechia
0.3360 -2
0.3625 -2
0.4530
-2
0.4720
-2
Denmark
-0.4879
0
-0.4174
0
0.3241
-2
0.2320
-4
Estonia
-0.4064
0
-0.5453 -3
-0.5575
0 -0.4687
-3
Finland
0.2042 -1
0.3163 -1
0.2151
-1
0.3073
-1
France
0.1186 -3
0.0953 -3
0.3601
-3
0.3447
-3
Germany
-0.4051 -4
0.2485 -2
-0.2671
-4 -0.2444
-3
Greece
-0.3189 -2
-0.2780 -2
0.2323
-4 -0.5138
-2
Hungary
0.3134 -2
0.3325 -2
0.3568
-2
0.3871
-2
Iceland
0.1725
0
0.2048
0
0.4786
-2
0.5073
-2
Italy
-0.2244 -1
-0.1366 -1
0.1433
-2
0.1483
-2
Japan
-0.4348 -3
-0.4360 -3
-0.5132
-4 -0.4810
-4
Korea
0.2466 -3
0.2706 -4
0.2753
0
0.3538
0
Latvia
-0.269 -4
-0.3248 -4
-0.3015
-4 -0.3418
-4
Lithuania
0.3482 -3
0.3191 -3
0.3958
-3
0.3826
-3
Luxembourg
0.1395 -1
0.1559 -1
-0.3993
-4 -0.3803
-2
Mexico
0.2019 -4
0.1590 -4
0.2582
-4
0.2053
-4
Netherlands
0.4802 -3
0.3696 -3
0.4230
-2
0.4046
-3
Norway
-0.2628 -2
-0.2239 -2
-0.3096
-3 -0.3179
-2
Poland
0.3710
0
0.3188
0
0.1800
-3
0.1548
-3
Portugal
-0.6214 -2
-0.6124 -2
-0.4449
-2 -0.4053
-2
Slovakia
0.1824 -4
0.1713 -4
-0.3631
-2 -0.3109
-2
Slovenia
0.4919
0
-0.3052 -1
0.5182
0 -0.3231
-1
Spain
0.3932 -1
0.2532 -3
-0.3352
-4
0.3311
-3
Sweden
0.3440 -4
0.4824 -4
-0.3389
0 -0.4275
0
Switzerland
0.2737 -3
-0.2029
0
0.4628
-3
0.4160
-3
United States
0.5358
0
-0.3319 -1
0.3025
-3 -0.1370
-4
Note: PGDP is the preventive care expenditure as a proportion of GDP, PCAP is the preventive care expenditure per capita,
HALE is the health adjusted life expectancy, and LE is life expectancy
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Appendix H1. Average annual GDP growth rate per capita by the cross-correlation of HALE and
preventive care spending per capita
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Appendix H2. Average annual GDP growth rate per capita by the cross-correlation of LE and preventive
care spending per capita
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Appendix I1. Average social protection expenditure per capita by the cross-correlation of HALE and
preventive care spending as a share of GDP
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Appendix I2. Average social protection expenditure per capita by the cross-correlation of LE and
preventive care spending as a share of GDP
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